AHA 2022: get the interventional cardiology perspective!

Condensed take-home messages from the American Heart Association Scientific Sessions 2022

Stay up to date with what is new and hot in interventional cardiology at #AHA22 in Chicago.

Mirvat Al Asnag, Ali Nazmi Calik, Daniele Giacoppo, Alex Sticchi, and Nicola Ryan provide their take on a selection of major late-breaking trials and studies of interest to the interventional cardiology community presented at AHA 2022!

ECMO-CS – Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results from the Multicenter, Randomized ECMO-CS Trial
BRIGHT-4 – Bivalirudin With a Post-PCI High-Dose Infusion versus Heparin Monotherapy During Primary PCI in STEMI: The Randomized Bright-4 Trial
OPTION – Efficacy and Safety of Indobufen versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial
PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial
SWAP-5 - Pharmacodynamic And Pharmacokinetic Profiles Of Switching Between Cangrelor And Ticagrelor Following Ticagrelor Pre-treatment